EP Patent

EP3802501A1 — Compounds as nuclear transport modulators and uses thereof

Assigned to XWPharma Ltd · Expires 2021-04-14 · 5y expired

What this patent protects

Provided are compounds of Formula I'-III', as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. Provided are also uses of the compounds or pharmaceutical compositions in treating or preve…

USPTO Abstract

Provided are compounds of Formula I'-III', as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. Provided are also uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological disorders and diseases as well as certain types of cancer in humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP3802501A1
Jurisdiction
EP
Classification
Expires
2021-04-14
Drug substance claim
No
Drug product claim
No
Assignee
XWPharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.